Urinary metabolomics reveals kynurenine pathway perturbation in newborns with transposition of great arteries after surgical repair

Manuela Simonato1,2 · Igor Fochi3 · Luca Vedovelli2 · Sonia Giambelluca4 · Cristiana Carollo1 · Massimo Padalino5 · Virgilio P. Carnielli6 · Paola Cogo7

Received: 9 May 2019 / Accepted: 10 October 2019 / Published online: 28 October 2019
© The Author(s) 2019

Abstract

Introduction Transposition of the great arteries (TGA) is a cyanotic congenital heart defect that requires surgical correction, with the use of cardiopulmonary-bypass (CPB), usually within 3 weeks of life. The use of CPB in open heart surgery results in brain hypoperfusion and in a powerful systemic inflammatory response and oxidative stress.

Objective We aimed to develop a novel untargeted metabolomics approach to detect early postoperative changes in metabolic profile following neonatal cardiac surgery.

Methods We studied 14 TGA newborns with intact ventricular septum undergoing arterial switch operation with the use of CPB. Urine samples were collected preoperatively and at the end of the surgery and were analyzed using an untargeted metabolomics approach based on UHPLC-high resolution mass spectrometry.

Results Since post surgery metabolic spectra were heavily contaminated by metabolites derived from administered drugs, we constructed a list of drugs used during surgery and their related metabolites retrieved from urine samples. This library was applied to our samples and 1255 drugs and drug metabolites were excluded from the analysis. Afterward, we detected over 39,000 unique compounds and 371 putatively annotated metabolites were different between pre and post-surgery samples. Among these metabolites, 13 were correctly annotated or identified. Metabolites linked to kynurenine pathway of tryptophan degradation displayed the highest fold change.

Conclusions This is the first report on metabolic response to cardiac surgery in TGA newborns. We developed an experimental design that allowed the identification of perturbed metabolic pathways and potential biomarkers of brain damage, limiting drugs interference in the analysis.

Keywords Untarget metabolomics · Transposition of great arteries · Kynurenine pathway · UHPLC-HRMS · Newborns

1 Introduction

D-loop Transposition of the Great Arteries (D-TGA) is the second most common form of cyanotic congenital heart disease (CHD). TGA accounts for 5% to 7% of all CHD,
with a birth prevalence of 0.31 per 1000 live births (95% CI 0.28–0.34) and male preponderance (van der Linde et al. 2011). The anatomical defect of D-TGA leads to cyanotic heart disease because of two parallel circulations. The first one sends deoxygenated systemic venous blood to the right atrium and back to the systemic circulation via the right ventricle and aorta; the second one sends oxygenated pulmonary venous blood to the left atrium and back to the lungs via the left ventricle and pulmonary artery. This will lead to profound hypoxic state pre- and postnatally until cardiac surgery is accomplished.

Survival without surgical repair is different among subset. It is very poor in untreated patients with D-TGA and intact ventricular septum: 80% at 1 week but only 17% at 2 months and 4% at 1 year (Mitchell et al. 1971). Neonatal arterial switch operation (ASO) is the treatment of choice for infants with D-TGA and it is usually performed within 3 weeks of life (Authors/Task Force et al. 2017).

Survival into adulthood after ASO is common, with a 20-year survival rate of nearly 90% (Villafane et al. 2014). However, early- and late-onset neurodevelopment (ND) abnormalities commonly occur. Although there has been a decline in gross neurological insults in D-TGA patients, many experienced behaviour, speech, and language delays at 4 and 8 years, with significant deficits in visual-spatial and memory skills as well as in components of executive functioning such as working memory and sustained attention between unperturbed and perturbed pathways could provide insight into underlying disease pathology and disease prognosis and diagnosis.

To the best of our knowledge, no studies have been published on the application of untargeted metabolomics to newborns with TGA undergoing cardiac surgery with CPB yet. Furthermore, relatively little is known about the metabolic changes that occur after cardiac surgery. A pilot study in children with different types of CHD found a difference in the metabolic profile of pre- and post-surgery plasma samples that returned toward baseline 48 h post-operatively (Correia et al. 2015). More recently, Davidson et al. (2018) used a targeted metabolomic approach to identify individual metabolites associated with post-operative complications in infants with less than 4 months undergoing cardiac surgery with CPB.

The metabolome is the final downstream product of gene transcription and protein translation; it changes rapidly, in timescales of minute to hours, and closely defines the phenotype. Because the dynamics of the human body are mirrored in the metabolome, we hypothesize that CPB-induced neuro-inflammation/oxidative damage could be associated with an altered urine metabolite composition. To address this hypothesis, we performed high resolution mass spectrometry-based untargeted metabolomic of urine samples collected before and after CPB from newborns with TGA and we developed a novel data analysis workflow useful to clear the metabolites deriving from administered drugs out of the urinary metabolic profile. The application of this workflow resulted in the: (i) identification of key biochemical pathways perturbed during cardiopulmonary-bypass (CPB) and ND and behavioral testing (Vedovelli et al. 2018).

In the peri- and post-operative phases, some centers use near infrared spectroscopy, transcranial Doppler, and measurement of biomarkers such as S100β and GFAP to identify infants at higher risk for ND abnormalities (Andropoulos et al. 2010). Despite their clear utility, the measured biomarker level provides only a partial snapshot of an individual’s current physiological state. While this provides useful information, single measurements do not give details about molecular pathway perturbations underpinning cardiac surgery-induced brain damage.

Metabolomics is a powerful approach to facilitate the detection of temporary physiological changes in real-time and allows its use as a monitoring approach for the potential surgery insult. Since many hundreds of small molecules are measured in parallel, a metabolomics experiment provides an individual metabolic profile, or fingerprint, for each analysed sample. Analyzing metabolic differences between unperturbed and perturbed pathways could provide insight into underlying disease pathology and disease prognosis and diagnosis.

The ability to identify those TGA newborns at greater risk of long-term disability would provide personalized neuroprotective and therapeutic strategies, and hence improve long-term outcome.

2 Methods

2.1 Patients

The study was approved by the institutional review board and by the ethics committee of the Padova University Hospital. Fourteen newborns undergoing ASO for TGA correction were recruited pre-operatively, with informed parental consent. The study was conducted at the Pediatric Cardiovascular Surgery Unit, Centro ‘V. Gallucci’, Padova University Hospital, Italy.

Exclusion criteria were age greater than 3 weeks, adjusted gestational age < 37 weeks, previous heart surgery, hemodynamic instability, respiratory failure, factor V less than 20%, creatinine clearance less than 30%, confirmed or suspected errors of metabolism or chromosomal, and major neurological abnormalities before surgery.
2.2 Patient biological samples

Urine samples were obtained from the urimeter of the Foley catheter system pre-operatively (at induction of anesthesia and before first surgical incision) and at the end of the surgery before initiation of modified ultrafiltration. Urine samples were centrifuged to remove cells and other debris. The supernatant was aliquoted and stored at −80 °C.

2.3 Sample processing

A “dilute-and-shoot” strategy was applied to the urine samples in order to minimize losses during sample preparation and because it is low time-consuming. Urine samples were thawed and centrifuged at 15,000×g for 20 min at 4 °C. Supernatant was diluted 1:5 and 1:2 with HPLC-grade water for positive (ESI+) and negative (ESI−) ionization analysis, respectively. Quality control (QC) samples were prepared by mixing equal volumes of all the urine samples. These pooled QC samples were prepared as described for real samples.

A procedural blank, used to monitor contamination acquired during all stages of sample preparation, a pool of the pre-surgery samples (pool-pre) and a pool of the post surgery samples (pool-post) were also prepared.

2.4 Chemicals and reagents

LC–MS grade methanol, water and formic acid as well as the standard mixtures used for the external calibration of the MS instrument were from Thermo Fisher Scientific (MA, USA). All analytical grade reference compound (glycocholic acid, d-tryptophan, N-acetyl-l-tryptophan, L-kynurenine and Kynurenic acid) were from Sigma Aldrich (Steinheim, Germany).

2.5 Liquid chromatography

The liquid chromatographic separation was done on a Thermo Scientific Dionex UltiMate 3000 RS system with a Hypersil Gold C-18 (100×2.1 mm, 3.0 μm, Thermo Fisher Scientific) column. The column was eluted at a flow rate of 300 μl/min with 80% of mobile phase A (0.02% formic acid in water) for 0.1 min followed by a linear gradient to 100% of mobile phase B (0.02% formic acid in methanol) over 20 min, then kept constant for 5 min, brought back to the initial conditions in 0.5 min, and maintained for 4 min. The column compartment and autosampler temperatures were set at 35 °C and 10 °C, respectively. The injection volume was 5 μl. Samples were randomly injected in triplicate to prevent any spurious classification deriving from the position of the sample in the sequence.

2.6 Mass spectrometry

A Q Exactive Classic mass spectrometer equipped with heated-ESI-II (HESI-II) ion source was employed (Thermo Fisher Scientific). Two analytical sequences (one in ESI+ and one in ESI- ionization mode) were executed. The capillary temperature was set at 300 °C. Nitrogen sheath gas was set at a flow rate of 45 arbitrary units (AU). Nitrogen auxiliary gas was set at a flow rate of 12 AU. The positive and negative spray voltage were 3.3 kV and 2.7 kV, respectively. Two acquisition modes were used with an m/z range 100–1200. A full MS scan at 70,000 resolution, an auto gain control target under 5×105 and a maximum injection time of 200 ms. The other acquisition mode was a full MS followed by data-dependent MS2 with a resolution of 17,500, an auto gain control target of 2×105, a maximum injection time of 50 ms, a loop count of top 5 peaks and an isolation window of m/z 1.0. All MS2 spectra of the compounds were acquired at two collision energies, 30 and 60 eV. XCalibur™ 4.1 software (Thermo Fisher Scientific) was used for data acquisition.

2.7 Generation of the drug metabolites list

A preliminary list of administered drugs (Table 1) and their endogenous metabolites was compiled using the “generate expected compound” node of the Compound Discoverer™ 2.1 (Thermo Fisher Scientific). The list includes parent compounds, administered drugs formula, and their possible transformation products. The “find expected compounds” node was used to search for compounds in the compound ions list provided by two “generate expected compound” nodes for every workflow. A more detailed illustration of this part of the workflow and its associated nodes is depicted in Fig. 1. Results were filtered for retention time (RT) greater than 1 min and groups area greater than or equal to 50,000 (Filter 1; Fig. 2). A mass list, called “exogenous drugs”, was created from the full-MS scans acquired from pre- and post-surgery pool samples.

2.8 Metabolomics workflow

The first experiment was conducted in Full MS mode. Procedural blank and 5 QC samples were injected in order to equilibrate the analytical platform. The QC were then injected at regular intervals (every 10 real samples) in order to check and correct the precision and reproducibility of individual mass spectral features (Dunn et al. 2011). Raw-files were processed by Compound Discoverer™ 2.1 using a processing workflow containing the “exogenous drugs” mass
list in the “search mass list” node. Results were filtered for RT (greater than 1 min) groups area (greater than or equal to 50,000), groups area ratio (pre- vs post-surgery sample: ≤ 0.2 or ≥ 5.0) and groups ratio p value (less than 0.05) and screened against the “exogenous drugs” mass list (mass tolerance 3 ppm, RT tolerance 0.5 min) (Filter 2; Fig. 2).

The identity of known compounds were verified based on HRMS, MS/MS fragmentation pattern and RT. The tentative identity of the discovered unknown compounds were assigned based on the interpretation of their CID-MS/MS (30 and 60 eV) fragmentation patterns. The workflow is depicted in Fig. 2.

2.9 Data analysis

Raw data files were processed by Compound Discoverer™ 2.1 software for initial data processing, including peak detection, peak alignment and peak integration. Briefly, raw files were aligned with adaptive curve setting with 5 ppm mass tolerance and 0.4 min retention time shift. Unknown compounds were detected with a 5 ppm mass tolerance, 3 signal to noise ratio, 30% of relative intensity tolerance for isotope search, and 500,000 minimum peak intensity, and then grouped with 5 ppm mass and 0.2 min retention time tolerances. A procedural blank sample was used for background substraction and noise removal during the pre-processing step. Peaks with less than a 3-fold increase, compared to blank samples, and those detected in less than 50% of QCs and where the relative standard deviation (%RSD) of the QCs was greater than 30% were removed from the list. Peak areas, across all samples, were subsequently normalized to the total area of the corresponding samples to balance their differences in intensities that may have arisen from instrument instability. Metabolites identified in the processed raw data of mass spectral peaks were searched against both ChemSpider™ chemical structure database (3 ppm mass tolerance) and mzCloud spectral library (precursor and fragment mass tolerance, 10 ppm). Five data sources were selected via the ChemSpider database: Human Metabolome Database (HMDB), Kyoto Encyclopaedia of Genes and Genomes (KEGG), LipidMAPS, Biocyc, and Drugbank.

Reference standards were used to validate and confirm some significantly changed metabolites by comparing their MS/MS spectra and retention time.

2.10 Statistical analysis

Clinical and surgical patient data were summarized using frequency and percentage for binary variables, whereas mean and standard deviation or median and range (min–max) were presented for continuous numeric variables (PASW Statistics 18.0, IBM Corp, Armonk, NY). Alterations in each compound were calculated using both a Student’s t test and a Student’s t-test with a Benjamini–Hochberg false discovery rate of 5% (Benjamini and Hochberg 1995). This yielded an adjusted p value for each metabolite termed q value. For each compound, groups area fold change was calculated and expressed as log2 scale (Compound Discoverer™ 2.1).
3 Results

Fourteen newborns with TGA undergoing elective ASO were included in this study. Baseline and surgical characteristics are shown in Table 2. The mean age at surgery was 9 (3–15) days and pre-operative oxygen saturation was 86 ± 7. There were no significative differences in surgical characteristics among patients.

All newborns received breast milk as minimal enteral feeding; feeding was discontinued at midnight before scheduled surgery in accordance with routine preoperative clinical practice. No major complications were observed after surgery.

3.1 Univariate analysis

A mass list called “exogenous drugs” was compiled and includes 4392 drugs and drugs metabolite.

From the Full MS scan experiment 16,890 and 28,102 compounds with unique molecular weight and retention times were annotated from the positive and the negative modes respectively (Volcano Plot, Supplemental data Fig. S1). After data cleaning to remove unreliable, inconsistent or unreproducible features (> 30% RSD\textsuperscript{QC}) and background subtraction, 9210 (ESI+) and 3081 (ESI−) compounds remained. Of these 11% (50%, ESI−) had RSD below 30%, 31% (28%, ESI-) below 20%, 29% (18%, ESI−) below 10% and, 29% (4%, ESI−) below 5%. Following data filtering 354 ESI(+) and 157 ESI(−) compounds remained and were subjected to a final visual inspection to eliminate compounds coming from in-source fragmentation of bigger molecules and metabolites deriving from naturally charged drugs (e.g. cisatracurium besylate, rocuronium bromide, vecuronium bromide and, nitroglycerin). In order to acquire MS\textsuperscript{2} information in the pre- and post-surgery pool samples m/z and RT values of each remaining compound were included in two target inclusion list (for each polarity). Raw
Data were added to the final analysis and the fragmentation scans were used only for the mzCloud search.

Raw data files were processed, and about 278 ESI+ and 93 ESI− metabolites remained after data filtering. Among the 371 discriminant metabolites (p < 0.05) this work led to the identification of 11 metabolites in human urine samples. The identification was either formally (when at least two physiochemical parameters, such as chromatographic retention time and MS/MS spectrum, matched those of our spectral library of reference compounds) or putatively (based on information from mzCloud and the interpretation of MS and MS/MS spectra), corresponding to levels 1 and 2 from the metabolomics standard initiative (Sumner et al. 2007) (Table 3).

Metabolites were distributed in 5 different pathways, including those regarding phenylalanine metabolism (N-phenylacetylglutamine), glucocorticoid byosynthesis (cortisol), tryptophan metabolism (indole-3-carboxaldehyde, indoleacrylic acid, kynurenic acid, tryptophan and 5-hydroxy-L-tryptophan), bile acid byosynthesis (glycocholic acid) and, omega-3 byosynthesis (eicosatetraynoic acid). Metabolites linked to the kynurenine pathway of tryptophan metabolism displayed the highest fold changes as high as 10.73 (log2) for tryptophan (Table 3).

Turning off the filters, we have found other two metabolites linked to the kynurenine pathway: kynurenine and 3-hydroxy-L-kynurenine (Table 3). N-Acetyl-tryptophan and 5-hydroxy-L-tryptophan were found both in positive and in negative polarity.

Using a critical q-value of 0.05, 7 metabolites were significantly altered even after post false discovery correction in the pre- vs post-surgery comparison.

---

Table 2 Baseline characteristics and surgical characteristics

| Characteristic                      | TGA |
|------------------------------------|-----|
| N                                  | 14  |
| Term n(%)                          | 13 (93) |
| Male sex n (%)                     | 11 (79) |
| Age at surgery (days)              | 9 (3-15) |
| Weight (Kg)                        | 3.2 ± 0.4 |
| SaO2 (%)                           | 86 ± 7 |

Surgical characteristics

| Type of operation | ASO |
|-------------------|-----|
| Operation time (min) | 230 ± 37 |
| CPB time (min)     | 142 ± 28 |
| Hypothermia time (min) | 100 ± 21 |
| Rewarming time (min) | 36 ± 14 |
| Minimum temperature (°C) | 27.8 ± 2.2 |
| Minimum temperature time (min) | 64 ± 33 |

TGA transposition of great arteries, SaO2, arterial oxygen saturation, CPB cardiopulmonary bypass, ASO arterial switch operation.

Values are expressed as frequency and percentage for binary variables, whereas mean and standard deviation or median and range (min–max) were presented for continuous numeric variables.
Table 3  Putatively annotated and identified metabolites

| Ion description                              | Detected m/z  | Predicted formula | Δmass ppm | RT (min) | RSD QC (%) | P      | q      | Ratio | Area fold change | ID level |
|----------------------------------------------|---------------|-------------------|-----------|----------|------------|--------|--------|-------|------------------|----------|
| N-Phenylacetylglutamine [M + Na]+1           | 287.09982     | C13 H16 N2 O4     | −1.13     | 2.89     | 5          | 0.004  | 0.040  | 9.238 | 3.21             | 2        |
| 20 β-Dihydrocortisol [M + Na]+1              | 365.23218     | C21 H32 O5        | 0.20      | 5.31     | 4          | 0.018  | 0.098  | 8.150 | 3.03             | 2        |
| Cortisol [M + Na]+1                          | 385.19824     | C21 H30 O5        | 0.57      | 10.05    | 7          | < 0.001| 0.007  | 0.170 | −2.55            | 2        |
| Indole-3-carboxaldehyde [M + H]+1            | 146.06001     | C9 H7 N O         | 0.25      | 5.28     | 4          | < 0.001| 0.001  | 0.018 | −5.83            | 2        |
| Eicosatetraynoic acid [M + H]+1              | 297.18481     | C20 H24 O2        | 0.15      | 4.74     | 11         | 0.005  | 0.051  | 0.072 | −3.79            | 2        |
| trans-3-Indoleacrylic acid [M + H]+1         | 188.07047     | C11 H9 N O2       | 0.72      | 5.28     | 4          | < 0.001| <0.001 | 0.002 | −9.04            | 2        |
| Glycocholic acid [M + Na]+1                  | 88.29858      | C26 H43 N O6      | 0.23      | 14.61    | 5          | 0.042  | 0.150  | 10.866| 3.44             | 1        |
| Kynurenic acid [M + H]+1                     | 190.04984     | C10 H7 N O3       | 0.37      | 2.58     | 0.4        | 0.004  | 0.047  | 9.895 | 3.31             | 1        |
| N-Acetyl-DL-tryptophan [M + H]+1             | 247.10748     | C13 H14 N2 O3     | 1.10      | 5.28     | 3          | < 0.001| <0.001 | 0.001 | −10.73           | 1        |
| D-(+)-Tryptophan [M + H−NH3]+1               | 188.07047     | C11 H12 N2 O2     | 0.67      | 5.28     | 1          | < 0.001| <0.001 | 0.001 | −10.35           | 1        |
| 5-hydroxy-L-tryptophan [M + H]+1             | 221.09193     | C11 H12 N2 O3     | 0.42      | 1.25     | 0.4        | 0.011  | 0.076  | 8.856 | 3.15             | 1        |
| Kynurenine [M + H]+1                         | 209.0212      | C10 H12 N2 O3     | 0.09      | 1.31     | 0.5        | 0.072  | 0.190  | 2.685 | 1.42             | 1        |
| 3-hydroxy-L-kynurenine [M + H + MeOH]+1       | 257.11285     | C10 H12 N2 O4     | 1.42      | 1.07     | 2          | 0.007  | 0.062  | 4.450 | 2.15             | 2        |

Ratio = pre/post
Putatively annotated (Level 2) and identified metabolites (Level 1). Univariate analysis (t-test) between groups. Bold font indicates metabolites that have passed the defined level of significance (p <0.05). Area fold change is expressed as log2 scale
4 Discussion

Metabolomics is a relatively young branch of “omics” science and has been applied to several studies in critical care and neonatal medicine (Fanos et al. 2013). However, previous untargeted metabolomic approach have ignored confounders such as drugs and feeding. Compounds deriving from the analysis of biological samples collected from critically ill infants are known to be contaminated by compounds deriving from treatments such as drugs and parenteral or enteral nutrition.

In this study the metabolic variation between pre- and post-surgery urine samples collected from TGA patients was investigated with high performance liquid chromatography coupled to FTMS for non-polar metabolites. Before and, above all, during cardiac surgery, several drugs are administered to our study newborns therefore the primary objective of this study was to develop a robust method to clear metabolites deriving from these drugs, out of the urinary metabolites profile. Our analytical approach enabled us to uncover the changes in urine composition strongly correlated with the surgery. To the best of our knowledge, this is the first time that a list of drugs, usually administered to critically ill infants, is compiled for this purpose. We believe that this novel approach will be extremely useful for the correct identification of endogenous metabolites triggered by an acute event, such as cardiac surgery in infants with CHD.

Metabolomic studies in infants with CHD undergoing CPB are scarce and they are designed to selectively extract information regarding a group of related metabolites from a complex mixture of biomolecules present in biological samples. Recently Correia et al. (2015) reported substantial differences in metabolic profile in pre- and post-operative plasma samples of patients with different types of CHD, moreover a significant difference in the preoperative metabolic fingerprints of neonates compared to older infants has been also observed (Davidson et al. 2018). Based on these results, we decided to use a homogeneous population, like TGA newborns, for our metabolomic study in order to overcome differences in metabolic profile due to age, surgery and/or disease severity, and to focus on CPB metabolic response only.

4.1 Interpretation of results

We found that urine metabolites profile of TGA patients changed after the surgery, in a direction that suggests a marked alteration in peripheral tryptophan (TRP) metabolism (Fig. 3) via the kynurenine pathway (KP). The KP pathway is initiated by the conversion of TRP to N-formylkynurenine by any of these enzymes: indoleamine 2,3-dioxygenase 1 (IDO1), IDO2, or tryptophan 2,3-dioxygenase (TD0). The resulting N-formylkynurenine is further degraded to kynurenine (KYN), which is a precursor of bioactive compounds, including quinolinic acid (QUIN), kynurenic acid (KYNA), picolinic acid, and 3-hydroxynicotinic acid. In mammals, the KP has been reported to account for over 90% of peripheral TRP catabolism (Leklem 1971) and plays a crucial role in the regulation of the immune response in the context of inflammation (Wirthgen and Hoeflich 2015). In the brain the various KP product can have either neurotoxic, neuroprotective or immunomodulatory effects (Vecsei et al. 2013). Among them, KYNA, mostly produced by astrocytes (Guillemin et al. 2001), is an antagonist of all ionotropic glutamate receptors and thus can potentially block some of the effects of the excitotoxin QUIN and of other neurotoxins. Furthermore, KYNA is an antioxidant capable of scavenging free radicals (Lugo-Huitron et al. 2011).

Our findings exhibit an increase in TRP, trans-3-indoleacrylic acid, indole-3-carboxaldehyde whereas 5-hydroxytryptophan, KYN, 3-hydroxy-KYN, and KYNA are decreased in the post-surgery urine samples. Interestingly, this dysregulation of the KP homeostasis also manifests in the blood of patients with neuroinflammatory diseases. KYNA was found to be decreased in the blood of patients suffering from glioblastoma (Adams et al. 2014) and in patients with Alzheimer’s and Parkinson’s diseases (Chatterjee et al. 2018; Lim et al. 2017) compared to healthy subjects. In addition to lower plasma level of KYNA, increased levels of KYN and KYNA were detected in glioblastoma cells and in the CSF of patients with Alzheimer’s disease where KYNA amount correlated with the expression of P-tau and the soluble intercellular adhesion molecule-1 which are biomarkers of inflammation (Opitz et al. 2011).

Elevated plasma or urine level of TRP along with lower peripheral level of KYNA and KYN in post- versus pre-surgery samples might reflect an increased synthesis and transport of KYN through the blood–brain barrier as a substrate for local synthesis of KYNA, knowing that KYNA is hardly able to cross the blood–brain barrier (Fukui et al. 1991). Thus, what is happening in the periphery may not represent what happens in the brain.

Open-heart surgery with application of CPB is known to be associated with acute activation of cellular and hormonal factors leading to postoperative stress response, clinically termed the systemic inflammatory response syndrome (SIDS). The CPB-generated inflammatory/stress response has been well demonstrated, and the younger the age of the child, the more robust is the response (Alcaraz et al. 2005). Cortisol is one of the most important stress hormones and its secretion is proportional and positively correlated to the severity of surgical stimuli (Bangalore et al. 2019). In
Urinary metabolomics reveals kynurenine pathway perturbation in newborns with transposition...

Our study group even in presence of pre-CPB glucocorticoid administration, we found a higher level of cortisol in post-surgery urine with respect to pre-surgery samples (Table 3) (Crow et al. 2014). Cortisol activates TDO and increases KYN production, which can be used as Kyna precursor (Niimi et al. 1983).

CPB carries significant risks to the brain. Neurodevelopmental impairment is emerging as one of the most important current challenges for survivors after pediatric cardiac surgery. Cerebral injury from cardiac surgery is primarily ischemic, secondary to embolism and/or cerebral hypoperfusion (Hogue et al. 2006). Neuronal injury is likely exacerbated by inflammatory processes resulting from CPB and ischemia/reperfusion (Laffey et al. 2002). The central nervous system has its own structures responsible for the neuroinflammation response, being microglia and reactive astrocytes the principal actors throughout the production of pro-inflammatory agents such as glutamate, TNF-α, prostaglandins, IL-6 and, reactive oxygen species (ROS) (Niranjan 2014). IDO 1 and IDO 2 are upregulated by inflammatory stimuli such as IFN-γ, TNF-α and lipopolysaccharides (Meyer et al. 1992), these two enzymes activates the KP pathway.

From all these data, we can suppose that during the CPB period, there is a rise in stress hormones (e.g. cortisol) and in inflammatory cytokines both in the periphery and in the brain. The subsequent induction of both TDO and IDO resulted in KP pathway activation with an increase in KYN production. Given the permeability of the blood brain barrier to KYN (Fukui et al. 1991) it can be taken up and metabolized within the CNS into Kyna by astrocytes, or into quinolinic acid (QUIN) by microglia. Kyna has anti-inflammatory, immunosuppressive and antioxidant functions. QUIN can lead to neuronal dysfunction and/or death whereas picolinic acid is neuroprotective and is an efficient metal chelator. Indole-3-aldehyde and indole acryl acid are produced by gut bacterial metabolism of TRP and can modulate CNS inflammation. TRP metabolites marked in bold have been found to be altered in the current study. Different colors indicate an increase (red) or decreases (blue) in metabolite area in the post- vs pre-surgery sample, (KEGG map 00380) (Color figure online)

Fig. 3 Alterations in tryptophan metabolism. About 90% of the tryptophan (TRP) is metabolized along the kynurenine (KYN) pathway (KP). 3% is metabolized into serotonin (5-OH-tryptamine) while, the rest is degraded by the gut microbiota to produce indole and its derivatives. In neuroinflammatory condition, the KP pathway is upregulated leading to the production of several neuroactive metabolites. Peripheral KYN and TRP can be transported across the blood brain barrier and be metabolized into kynurenic acid (Kyna), by astrocytes, or into quinolinic acid (QUIN) by microglia.
TRP, under conditions generating free radicals (Ramos-Chavez et al. 2018). We also identified two metabolites, indole-3-carboxaldehyde and indoleacrylic acid, which are are exclusively produced by gut bacterial metabolism of TRP (Gao et al. 2018). Beneficial effect of indoleacrylic acid has been proposed, hinged on its ability to promote intestinal epithelial barrier function and mitigates inflammatory responses (Wlodarska et al. 2017). Indole-3-carboxaldehyde is a biologically active metabolite which act as a receptor agonist at the aryl hydrocarbon receptor in intestinal immune cells, stimulating the production of IL-22 which facilitates mucosal reactivity (Zelante et al. 2013). Furthermore, has been recently demonstrated that the metabolites of dietary TRP produced by the commensal flora modulate microglia-astrocyte interactions and CNS inflammation (Rothhammer et al. 2018).

Among the identified metabolites, other 2 were part of the KP pathway, 5-hydroxy-L-tryptophan and 3-hydroxy-L-kynurenine which were higher in the pre- with respect to the post-surgery sample. Tryptophan is an essential precursor for KP pathway as well for serotonin/melatonin pathway. During acute or chronic inflammation, TRP is preferentially catabolized through the KP route rather than serotonin/melatonin pathway resulting in a decrease of serotonin production. This was supported by a decrease, in our post-surgery sample, of 5-hydroxy-L-tryptophan that give rise to serotonin and melatonin.

Kynurenine-3-monooxygenase converts KYN into the neurotoxic free-radical generator, 3-hydroxy-L-kynurenine, which can be taken up by kynurenine aminotransferase to produce xanthurenic acid. 3-hydroxy-L-kynurenine is lower in the post-surgery samples indicating a down-regulation of this branch with a preferential transport of KYN to the brain for KYNA synthesis.

### 4.2 Strengths and limitations of the study

To our knowledge, this work is the first metabolomic study in TGA newborns undergoing surgery for CHD. This study demonstrates that we can accurately clear out metabolites deriving from administered drugs, and that changes occur in the metabolic profile as response to the surgical insult.

This study has weakness and strength. The main weakness is that our pilot study is limited by its small sample size and larger studies are needed to validate our results. Moreover, we are aware that we can correct for the drug metabolites but nonetheless it can not be ruled out the effect of the administered drugs on the overall metabolism. However, a significant strength of the study was the data analysis workflow built to overcome the confounding factors, this makes possible to reliably measure the changes of markers of interest.

### 4.3 Clinical implications and future directions

The untargeted approach used in this study showed the power to explore metabolites that differentiate between pre- and post-surgery samples. The differentiating metabolites found in this work have guided our focus to the kynurenine pathway. With confidence we can now progress these metabolites to a quantitative targeted metabolomic analysis in a larger cohort of CHD patients. The amount of these metabolites will be correlated to our gold standard of impaired neurodevelopment, GFAP, and with data obtained from post-surgery neurological and neurodevelopmental test. This may provide the robust biomarker panel needed for prediction of brain damage. Early identification of patients at risk for adverse neurodevelopmental outcomes is of paramount importance for both preemptive interventions and actuation of assisted neurodevelopment programs.

**Author contributions** PC, MP, and VPC conceived and designed the project. CC collected samples for the study. LV coordinated the project. SG performed samples preparation. MS and IF designed and conducted the untargeted analysis. MS wrote the first draft of the manuscript. All authors have read and approved the manuscript.

**Funding** This study was funded from the Just Foundation grant 2016 (PC)

**Compliance with ethical standards**

**Conflict of interest** The authors declare no conflict of interest.

**Ethical approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (Protocol number 3142/AO/14, Padova University Hospital, Padova, Italy) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed consent** Parental informed consent was obtained for each patient included in this study.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

Adams, S., Teo, C., McDonald, K. L., Zinger, A., Bustamante, S., Lim, C. K., et al. (2014). Involvement of the kynurenine pathway in human glioma pathophysiology. *PLoS ONE, 9*, e112945.

Alcaraz, A. J., Manzano, L., Sancho, L., Vigil, M. D., Esquivel, F., Maroto, E., et al. (2005). Different proinflammatory cytokine serum pattern in neonate patients undergoing open heart surgery. *Relevance of IL-8. Journal of Clinical Immunology, 25*, 238–245.
Andropoulos, D. B., Brady, K. M., Easley, R. B., & Fraser, C. D., Jr. (2010). Neuroprotection in pediatric cardiac surgery: What is on the horizon? Progress in Pediatric Cardiology, 29, 113–122.

Authors/Task Force, M., Sarris, G. E., Balmer, C., Bonou, P., Comas, J. V., da Cruz, E., Di Chiara, L., Di Donato, R. M., Fragata, J., Jokinen, T. E., Kirvassilis, G., Lytrivi, I., Milojevic, M., Sharland, G., Siepe, M., Stein, J., Buchel, E. V., & Vouhe, P. R. (2017). Clinical guidelines for the management of patients with transposition of the great arteries with intact ventricular septum. Cardiology in the Young, 27, 530–569.

Bangalore, H., Checchia, P. A., Ocampo, E. C., Heine, J. S., Minard, C. G., & Shekerdemian, L. S. (2019). Cortisol response in children after second cardiopulmonary bypass. Pediatric Cardiology, 40, 47–52.

Bellinger, D. C., Wypij, D., duPlessis, A. J., Rappaport, L. A., Jonas, R. A., Wernovsky, G., et al. (2003). Neurodevelopmental status at eight years in children with dextro-transposition of the great arteries: The Boston Circulatory Arrest Trial. Journal of Thoracic and Cardiovascular Surgery, 126, 1385–1396.

Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate—a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B, 57, 289–300.

Chatterjee, P., Goozee, K., Lim, C. K., James, I., Shen, K., Jacobs, K. R., et al. (2018). Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-beta load: A pilot study. Scientific Reports, 8, 8008.

Correira, G. D., Wosi Ng, K., Wijeyesekera, A., Gala-Peralta, S., Williams, G., MacCarthy-Morrogh, S., et al. (2015). Metabolic profiling of children undergoing surgery for congenital heart disease. Critical Care Medicine, 43, 1467–1476.

Crow, S. S., Oliver, W. C., Jr., Kiefer, J. A., Snyder, M. R., Dearani, J. A., Li, Z., et al. (2014). Dexamethasone levels predict cortisol response after infant cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 147, 475–481.

Davidsson, J. A., Pfeifer, Z., Frank, B., Tong, S., Urban, T. T., Wischmeyer, P. A., et al. (2018). Metabolomic fingerprinting of infants undergoing cardiopulmonary bypass: Changes in metabolic pathways and association with mortality and cardiac intensive care unit length of stay. Journal of the American Heart Association, 7, e010711.

Dunn, W. B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., Anderson, N., et al. (2011). Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nature Protocols, 6, 1060–1083.

Fanos, V., Iacovidou, N., Puddu, M., Ottonello, G., Noto, A., & Atzori, L. (2013). Metabolomics in neonatal life. Early Human Development, 89(Suppl 1), S7–S10.

Fukui, S., Schwarcz, R., Rapoport, S. I., Takada, Y., & Smith, Q. R. (1991). Blood-brain barrier transport of kynurenines: Implications for brain synthesis and metabolism. Journal of Neurochemistry, 56, 2007–2017.

Gao, J., Xu, K., Liu, H., Liu, G., Bai, M., Peng, C., et al. (2018). Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Frontiers in Cellular and Infection Microbiology, 8, 13.

Guillen, G. J., Kerr, S. J., Smythe, G. A., Smith, D. G., Kapoor, V., Armati, P. J., et al. (2001). Kynurenine pathway metabolism in human astrocytes: A paradox for neuronal protection. Journal of Neurochemistry, 78, 842–853.

Hogue, C. W., Jr., Palin, C. A., & Arrowsmith, J. E. (2006). Cardiopulmonary bypass management and neurologic outcomes: An evidence-based appraisal of current practices. Anesthesia and Analgesia, 103, 21–37.

Laffey, J. G., Boylan, J. F., & Cheng, D. C. (2002). The systemic inflammatory response to cardiac surgery: Implications for the anesthesiologist. Anesthesiology, 97, 215–252.

Leklem, J. E. (1971). Quantitative aspects of tryptophan metabolism in humans and other species: A review. American Journal of Clinical Nutrition, 24, 659–672.

Lim, C. K., Fernandez-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., et al. (2017). Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease. Progress in Neurobiology, 155, 76–95.

Lugo-Huitron, R., Blanco-Ayala, T., Ugalde-Muniz, P., Carrillo-Mora, P., Pedraza-Chaverri, J., Silva-Adaya, D., et al. (2011). On the antioxidative properties of kynurenic acid: Free radical scavenging activity and inhibition of oxidative stress. Neurotoxicology and Teratology, 33, 538–547.

Meyer, K. C., Cornwell, R., Carlin, J. M., Powers, C., Irizarry, A., Byrne, G. I., et al. (1992). Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: Synergy with lipopolysaccharide. American Journal of Respiratory Cell and Molecular Biology, 6, 639–646.

Mitchell, S. C., Korones, S. B., & Berendes, H. W. (1971). Congenital heart disease in 56,109 births. Incidence and natural history. Circulation, 43, 323–332.

Niimi, S., Nakamura, T., Nawa, K., & Ichihara, A. (1983). Hormonal regulation of translatable mRNA of tryptophan 2,3-dioxygenase in primary cultures of adult rat hepatocytes. Journal of Biochemistry, 94, 1697–1706.

Niranjjan, R. (2014). The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: Focus on astrocytes. Molecular Neurobiology, 49, 28–38.

Opite, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tischtrich, I., Trump, S., et al. (2011). An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 478, 197–203.

Ramos-Chavez, L. A., Lugo Huitron, R., Gonzalez Esquivel, D., Pineda, B., Rios, C., Silva-Adaya, D., et al. (2018). Relevance of alternative routes of kynurenic acid production in the brain. Oxidative Medicine and Cellular Longevity, 2018, 5272741.

Rothhammer, V., Borucki, D. M., Tjon, E. C., Takenaka, M. C., Chao, C. C., Ardua-Fabregat, A., et al. (2018). Microglial control of astrocytes in response to microbial metabolites. Nature, 557, 724–728.

Sumner, L. W., Amberg, A., Barrett, D., Beale, M. H., Beger, R., Daykin, C. A., et al. (2007). Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) metabolomics standards initiative (MSI). Metabolomics, 3, 211–221.

van der Linde, D., Konings, E. E., Slager, M. A., Witsenburg, M., Helbing, W. A., Takkenberg, J. J., et al. (2011). Birth prevalence of congenital heart disease worldwide: A systematic review and meta-analysis. Journal of the American College of Cardiology, 58, 2241–2247.

Vecsei, L., Szalardy, L., Fulop, F., & Toldi, J. (2013). Kynurenines in the CNS: Recent advances and new questions. Nature Reviews Drug Discovery, 12, 64–82.

Vedovelli, L., Padalino, M., Suppiej, A., Sartori, S., Falasco, G., Simonato, M., et al. (2018). Cardiopulmonary-bypass glial fibrillary acidic protein correlates with neurocognitive skills. Annals of Thoracic Surgery, 106, 792–798.
Villafane, J., Lantin-Hermoso, M. R., Bhatt, A. B., Tweddell, J. S., Geva, T., Nathan, M., et al. (2014). D-transposition of the great arteries: the current era of the arterial switch operation. *Journal of the American College of Cardiology, 64*, 498–511.

Wirthgen, E., & Hoeflich, A. (2015). Endotoxin-induced tryptophan degradation along the kynurenine pathway: The role of indoleamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immunosuppressive effects in endotoxin tolerance and cancer and its implications for immunoparalysis. *Journal of Amino Acids, 2015*, 973548.

Wlodarska, M., Luo, C., Kolde, R., d’Hennezel, E., Annand, J. W., Heim, C. E., et al. (2017). Indoleacrylic acid produced by commensal peptostreptococcus species suppresses inflammation. *Cell Host & Microbe, 22*(25–37), e6.

Zelante, T., Iannitti, R. G., Cunha, C., De Luca, A., Giovannini, G., Pieraccini, G., et al. (2013). Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity, 39*, 372–385.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.